250 related articles for article (PubMed ID: 16087778)
1. Reexamination of the TEMPO Study.
Shults CW
Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778
[No Abstract] [Full Text] [Related]
2. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
3. [The early therapy challenge].
Reichmann H
Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310
[No Abstract] [Full Text] [Related]
4. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
5. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
6. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
7. Clinical trials of neuroprotection for Parkinson's disease.
LeWitt PA
Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583
[No Abstract] [Full Text] [Related]
8. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
Chen JJ; Swope DM
J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
10. [What strategies are recommended for early stage disease? Other treatments].
Damier P
Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044
[No Abstract] [Full Text] [Related]
11. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
12. Rasagiline in Parkinson's disease: the show must go on.
Jost WH
Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
[No Abstract] [Full Text] [Related]
13. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
14. Preclinical versus clinical neuroprotection.
Grünblatt E; Schlösser R; Gerlach M; Riederer P
Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
[No Abstract] [Full Text] [Related]
15. Neuroprotection by selegiline and other MAO inhibitors.
Stern G
J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
[TBL] [Abstract][Full Text] [Related]
16. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
17. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
18. Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O
Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
[No Abstract] [Full Text] [Related]
19. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
20. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
